Phase 1/2

Bavarian Nordic is leveraging its MVA-BN platform technology to advance its next generation of immuno-oncology candidates. The Company aims to activate a targeted immune response, arming the body’s own immune system to seek and destroy cancer cells. 

Providing the body with as many tools as possible significantly increases its chances to eradicate the disease. This tactic includes: priming antigen-specific T-cell activation; inducing T-cell expansion, migration and invasion into tumor sites; modifying tumor microenvironments to allow T-cell function and killing; induction of natural killer cells to account for tumor cells that cannot be recognized by T-cells; and overcoming T-cell inhibitory (checkpoint) signals. 

A tumor antibody enhanced therapeutic vaccine (TAEK-VAC) targeting HER2 and brachyury has been generated from the MVA-BN platform. A Phase 1/2 open label trial of intravenous administration of the vaccine, was initiated in early 2021 in patients with advanced HER2- and brachyury-expressing cancers.